Limited durability of viral control following treated acute HIV infection

被引:142
作者
Kaufmann, DE
Lichterfeld, M
Altfeld, M
Addo, MM
Johnston, MN
Lee, PK
Wagner, BS
Kalife, ET
Strick, D
Rosenberg, ES
Walker, BD [1 ]
机构
[1] Harvard Univ, Sch Med, Partners AIDS Res Ctr,Infect Dis Unit, Massachusetts Gen Hosp, Boston, MA USA
[2] Harvard Univ, Sch Med, Div Aids, Boston, MA USA
[3] Harvard Univ, Sch Med, Howard Hughes Med Inst, Massachusetts Gen Hosp, Boston, MA USA
关键词
D O I
10.1371/journal.pmed.0010036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute HIV-1 infection. Methods and Findings Fourteen patients were treated during acute HIV-1 infection and subsequently subjected to an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%) patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d following one, two, or three interruptions of treatment. However, a gradual increase in viremia and decline in CD4+ T cell counts was observed in most individuals. By an intention-to-treat analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4+ and CD8+ T cell responses. The magnitude of HIV-1-specific cellular immune responses before treatment interruption did not predict duration of viremia control. The small sample size and lack of concurrent untreated controls preclude assessment of possible clinical benefit despite failure to control viremia by study criteria. Conclusions These data indicate that despite initial control of viremia, durable viral control to less than 5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs infrequently. Determination of whether early treatment leads to overall clinical benefit will require a larger and randomized clinical trial. These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve.
引用
收藏
页码:137 / 148
页数:12
相关论文
共 64 条
[1]   Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load [J].
Addo, MM ;
Yu, XG ;
Rathod, A ;
Cohen, D ;
Eldridge, RL ;
Strick, D ;
Johnston, MN ;
Corcoran, C ;
Wurcel, AG ;
Fitzpatrick, CA ;
Feeney, ME ;
Rodriguez, WR ;
Basgoz, N ;
Draenert, R ;
Stone, DR ;
Brander, C ;
Goulder, PJR ;
Rosenberg, ES ;
Altfeld, M ;
Walker, BD .
JOURNAL OF VIROLOGY, 2003, 77 (03) :2081-2092
[2]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[3]   HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus [J].
Altfeld, M ;
Allen, TM ;
Yu, XG ;
Johnston, MN ;
Agrawal, D ;
Korber, BT ;
Montefiori, DC ;
O'Connor, DH ;
Davis, BT ;
Lee, PK ;
Maier, EL ;
Harlow, J ;
Goulder, PJR ;
Brander, C ;
Rosenberg, ES ;
Walker, BD .
NATURE, 2002, 420 (6914) :434-439
[4]   Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences [J].
Altfeld, M ;
Addo, MM ;
Shankarappa, R ;
Lee, PK ;
Allen, TM ;
Yu, XG ;
Rathod, A ;
Harlow, J ;
O'Sullivan, K ;
Johnston, MN ;
Goulder, PJR ;
Mullins, JI ;
Rosenberg, ES ;
Brander, C ;
Korber, B ;
Walker, BD .
JOURNAL OF VIROLOGY, 2003, 77 (13) :7330-7340
[5]   Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection [J].
Altfeld, M ;
Rosenberg, ES ;
Shankarappa, R ;
Mukherjee, JS ;
Hecht, FM ;
Eldridge, RL ;
Addo, MM ;
Poon, SH ;
Phillips, MN ;
Robbins, GK ;
Sax, PE ;
Boswell, S ;
Kahn, JO ;
Brander, C ;
Goulder, PJR ;
Levy, JA ;
Mullins, JI ;
Walker, BD .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (02) :169-180
[6]   Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes [J].
Barouch, DH ;
Kunstman, J ;
Kuroda, MJ ;
Schmitz, JE ;
Santra, S ;
Peyerl, FW ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Gorgone, DA ;
Montefiori, DC ;
Lewis, MG ;
Wolinsky, SM ;
Letvin, NL .
NATURE, 2002, 415 (6869) :335-339
[7]   Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses:: Relationship to viral load in untreated HIV infection [J].
Betts, MR ;
Ambrozak, DR ;
Douek, DC ;
Bonhoeffer, S ;
Brenchley, JM ;
Casazza, JP ;
Koup, RA ;
Picker, LJ .
JOURNAL OF VIROLOGY, 2001, 75 (24) :11983-11991
[8]   Impact of hepatitis G virus co-infection on the course of hepatitis C virus infection before and after liver transplantation [J].
Bizollon, T ;
Guichard, S ;
Ahmed, SNS ;
Chevallier, P ;
Ducerf, C ;
Sepetjan, M ;
Baulieux, J ;
Trepo, C .
JOURNAL OF HEPATOLOGY, 1998, 29 (06) :893-900
[9]   Presence of HIV-1 gag-specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection [J].
Boaz, MJ ;
Waters, A ;
Murad, S ;
Easterbrook, PJ ;
Vyakarnam, A .
JOURNAL OF IMMUNOLOGY, 2002, 169 (11) :6376-6385
[10]   Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection [J].
Carcelain, G ;
Tubiana, R ;
Samri, A ;
Calvez, V ;
Delaugerre, C ;
Agut, H ;
Katlama, C ;
Autran, B .
JOURNAL OF VIROLOGY, 2001, 75 (01) :234-241